Xaluprine (previously Mercaptopurine Nova Laboratories)

RSS

mercaptopurine

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Xaluprine. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Xaluprine.

This EPAR was last updated on 15/12/2022

Authorisation details

Product details
Name
Xaluprine (previously Mercaptopurine Nova Laboratories)
Agency product number
EMEA/H/C/002022
Active substance
6-mercaptopurine monohydrate
International non-proprietary name (INN) or common name
mercaptopurine
Therapeutic area (MeSH)
Leukemia, Lymphoid
Anatomical therapeutic chemical (ATC) code
L01BB02
Publication details
Marketing-authorisation holder
Nova Laboratories Ireland Limited
Revision
14
Date of issue of marketing authorisation valid throughout the European Union
09/03/2012
Contact address

3rd Floor, Ulysses House
Foley Street
Dublin 1, D01 W2T2
Ireland

Product information

09/11/2022 Xaluprine (previously Mercaptopurine Nova Laboratories) - EMEA/H/C/002022 - IA/0037/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Xaluprine is indicated for the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating
Average
2 ratings
1 rating